Scripps Research Translational Institute, Scripps Research, La Jolla, CA 92037, USA; Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA.
Scripps Research Translational Institute, Scripps Research, La Jolla, CA 92037, USA; Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037, USA.
Cell Metab. 2024 Apr 2;36(4):670-683. doi: 10.1016/j.cmet.2024.02.002. Epub 2024 Feb 29.
The rise of artificial intelligence (AI) has revolutionized various scientific fields, particularly in medicine, where it has enabled the modeling of complex relationships from massive datasets. Initially, AI algorithms focused on improved interpretation of diagnostic studies such as chest X-rays and electrocardiograms in addition to predicting patient outcomes and future disease onset. However, AI has evolved with the introduction of transformer models, allowing analysis of the diverse, multimodal data sources existing in medicine today. Multimodal AI holds great promise in more accurate disease risk assessment and stratification as well as optimizing the key driving factors in cardiometabolic disease: blood pressure, sleep, stress, glucose control, weight, nutrition, and physical activity. In this article we outline the current state of medical AI in cardiometabolic disease, highlighting the potential of multimodal AI to augment personalized prevention and treatment strategies in cardiometabolic disease.
人工智能(AI)的兴起彻底改变了各个科学领域,尤其是医学领域,它使我们能够从大量数据集中建立复杂关系的模型。最初,人工智能算法侧重于改进对胸部 X 光和心电图等诊断研究的解释,以及预测患者的结局和未来疾病的发作。然而,随着转换器模型的引入,人工智能也得到了发展,使得对当今医学中存在的各种多模态数据源的分析成为可能。多模态人工智能在更准确的疾病风险评估和分层以及优化心血管代谢疾病的关键驱动因素方面具有很大的潜力:血压、睡眠、压力、血糖控制、体重、营养和身体活动。在本文中,我们概述了心血管代谢疾病中医疗 AI 的现状,强调了多模态 AI 增强心血管代谢疾病个性化预防和治疗策略的潜力。